Trevi Therapeutics, Inc.
TRVINasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$49.3M | −$51.5M | −$33.9M | −$29.9M | −$32.5M | −$32.5M |
| Net income | −$42.8M | −$47.9M | −$29.1M | −$29.2M | −$33.9M | −$32.8M |
| Total assets | $193.4M | $110.9M | $89.4M | $123.0M | $38.5M | $47.1M |
| Total liabilities | $10.2M | $11.3M | $6.9M | $15.6M | $21.4M | $19.8M |
| Equity | $183.2M | $99.6M | $82.5M | $107.5M | $17.1M | $27.3M |
| EPS (diluted) | $-0.32 | $-0.47 | $-0.29 | $-0.45 | $-1.49 | — |
| Shares out. | 96.7M | 69.0M | 60.0M | 30.8M | 19.9M | 17.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −23.3%
- Return on assets
- −22.1%
- Return on capital (ROCE)
- −26.9%
- Liabilities / assets
- 5.3%
- Debt / equity
- 0.06×
- Book value / share
- $1.90
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 17.77safe
- Accruals / assets
- −0.3%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-04A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
- Phase 1Recruitingreadout ~2026-06-30NAL ER IPF Respiratory Function and Safety Study
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- New Enterprise Associates 16, L.P.Activist (13D)May 7, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Rubric Capital Management LpPassive (13G)Feb 13, 2026
- Frazier Life Sciences Public Fund, L.P.Passive (13G)Nov 14, 2025
- Viking Global Investors LpPassive (13G)Nov 14, 2025
- Blackrock, Inc.Passive (13G)Oct 17, 2025
- Venrock Healthcare Capital Partners Ii, L.P.Passive (13G)Feb 14, 2025
- Rosalind Advisors, Inc.Passive (13G)Feb 13, 2025
- Mai Capital ManagementPassive (13G)Jul 10, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Galletta ChristopherOfficer — See Remarks | Dec 2, 2025 | Option exercise | 4,225 | $0.51 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 13.3M | 8.7 | -13.1% |
| Apr 30, 2026 | 15.3M | 6.7 | -5.3% |
| Apr 15, 2026 | 16.1M | 13.4 | +5.5% |
| Mar 31, 2026 | 15.3M | 11.3 | -7.0% |
| Mar 13, 2026 | 16.4M | 12.1 | -2.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Entered a material agreement · Results of operations · Other material eventApr 17, 2026
- Results of operationsMar 17, 2026
- Other material eventMar 9, 2026
- Director / officer changeDec 5, 2025
- Results of operationsNov 13, 2025
- Director / officer changeAug 20, 2025
- Results of operationsAug 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13D/AMay 7, 2026
- SCHEDULE 13G/AMay 6, 2026
- 10-QMay 5, 2026
- 8-KMay 5, 2026
- DEF 14AApr 21, 2026
- DEFA14AApr 21, 2026
- ARSApr 21, 2026
- 424B5Apr 17, 2026
- 8-KApr 17, 2026
- 424B5Apr 16, 2026
- PRE 14AApr 10, 2026
- SCHEDULE 13G/AMar 27, 2026
- 10-KMar 17, 2026
- 8-KMar 17, 2026
- 8-KMar 9, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.